{"protocolSection":{"identificationModule":{"nctId":"NCT02099006","orgStudyIdInfo":{"id":"46905"},"organization":{"fullName":"University of Rochester","class":"OTHER"},"briefTitle":"Novel Topical Therapies for the Treatment of Genital Pain","officialTitle":"Novel Topical Therapies for the Treatment of Genital Pain","acronym":"Topicals"},"statusModule":{"statusVerifiedDate":"2016-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-11"},"primaryCompletionDateStruct":{"date":"2015-06","type":"ACTUAL"},"completionDateStruct":{"date":"2015-06","type":"ACTUAL"},"studyFirstSubmitDate":"2014-03-25","studyFirstSubmitQcDate":"2014-03-25","studyFirstPostDateStruct":{"date":"2014-03-28","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-07-14","resultsFirstSubmitQcDate":"2016-07-14","resultsFirstPostDateStruct":{"date":"2016-07-15","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-07-14","lastUpdatePostDateStruct":{"date":"2016-07-15","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Adrienne Bonham","investigatorTitle":"Associate Professor","investigatorAffiliation":"University of Rochester"},"leadSponsor":{"name":"University of Rochester","class":"OTHER"},"collaborators":[{"name":"Mae Stone Goode Foundation","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study is testing drugs not previously used topically for the treatment of vulvodynia, a common genital pain syndrome. It is hoped that one of these drugs will improve vaginal entryway pain with touch, daily pain scores and sexual functioning.","detailedDescription":"Vulvodynia is defined as burning pain, occurring in the absence of any visible finding or a clinically identifiable nervous disorder. Current treatments include vulvar care measure, topical medications, oral medications, biofeedback, physical therapy and surgery. The usual treatment is to have the patient take either tricyclic antidepressants or anti convulsants orally, however these methods seldom bring total relief. These drugs do have significant side effects limiting the patient's tolerance of the higher does sometimes needed. An effective topical medication would greatly benefit these women with fewer side effects and better tolerance. Topical amitriptyline and baclofen are often prescribed, but no studies have been done to support their use. Topical gabapentin has also been shown to have good effect, but no prospective clinical study as been done.\n\nThis study will test topical application of Cetaphil, Loperamide, Gabapentin, Ketoprofen, Ketamine and Amitriptyline over a 19 week period in the first phase of the study. The drugs are compounded by the University of Rochester research pharmacy and dispensed in 19 vials, one vial to be used each week. Patients and study personnel are blinded as to which drug is being used. Each study participant was given a week of placebo at the initiation of the study. Each study compound, which contains both the drug and the base (Cetaphil) will be used twice a day for two weeks in a row, followed by a one week washout of base alone. If a patient finds that one of the drugs is effective she may stop participation after the first 13 weeks and request that the most effective drug be prescribed for her. The unblinding officer would then work with the research pharmacy to identify the effective drug and provide the patient with a prescription for that drug. If the patient desires, she may enroll in the second phase of the study when she will test the last two drugs over a six week period with the washout as in the first segment of the study. The drugs would be administered in vials as in the first section of the study.\n\nEvery week on Sunday the patient will complete an electronic diary, recording her daily pain, any drug side effects, pain with the tampon test and overall health. Every three weeks she will complete the Female Sexual Function Index on the same electronic system. She would start her new drug on Monday each week. Additionally the coordinator of the study will call each patient on Wednesday to see if they are having any problems with the drug started on Monday.\n\nAll patients who could become pregnant are required to maintain effective contraception throughout the study."},"conditionsModule":{"conditions":["Female Genital Diseases"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":9,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Medications","type":"EXPERIMENTAL","description":"Each study subject will be sequentially exposed to each of the study drugs and the placebo in a random order. The study is designed as a double blinded, crossover study.","interventionNames":["Drug: Amitriptyline","Drug: Baclofen","Drug: Ketoprofen","Drug: Ketamine","Drug: Loperamide","Drug: Gabapentin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"The compounding base alone will be used as a placebo. Each participant will be given each drug and the placebo sequentially in random order.","interventionNames":["Drug: placebo"]}],"interventions":[{"type":"DRUG","name":"Amitriptyline","description":"Topical application of the drug at a 2% concentration in combination with 2% Baclofen","armGroupLabels":["Medications"],"otherNames":["Elavil"]},{"type":"DRUG","name":"Baclofen","description":"Used topically at 2% concentration in combination with 2% amitriptyline","armGroupLabels":["Medications"],"otherNames":["Lioresal"]},{"type":"DRUG","name":"Ketoprofen","description":"To be applied topically at a 10% concentration","armGroupLabels":["Medications"],"otherNames":["Orudis","Oruvail","Nexcede","Orudis KT"]},{"type":"DRUG","name":"Ketamine","description":"To be applied topically at a 10% concentration","armGroupLabels":["Medications"],"otherNames":["Ketalar"]},{"type":"DRUG","name":"Loperamide","description":"To be applied topically at a 5% concentration","armGroupLabels":["Medications"],"otherNames":["Imodium","Imotil","Kaopectate"]},{"type":"DRUG","name":"Gabapentin","description":"To be applied topically at a 6% concentration","armGroupLabels":["Medications"],"otherNames":["Neurontin"]},{"type":"DRUG","name":"placebo","description":"Compounding base to be used alone as a placebo","armGroupLabels":["Placebo"],"otherNames":["Cetaphil"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Reduction in Daily Genital Pain.","description":"Each subject was asked to keep a symptom diary recording her daily genital pain, measured on a 10 point Likert scale. A score of \"0\" was defined as no pain and a score of \"10\" was defined as worst imaginable pain. These daily values were collected and a mean pain score for the period of treatment was calculated.","timeFrame":"13 weeks"}],"secondaryOutcomes":[{"measure":"Reduction in Tampon Test Pain","description":"Reduction in the pain, as measured on a 10 point Likert scale, associated with the insertion and removal of a tampon. This is a validated surrogate for pain associated with intercourse. Subjects were asked to insert and remove a tampon each week and report the degree of pain associated with this. A score of \"0\" was defined as no pain, and a score of \"10\" was defined as worst imaginable pain.","timeFrame":"13 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women between ages of 18 and 65 who complain of localized provoked vulvar pain and meet the criteria for the diagnosis of localized provoked vulvodynia. Patients who have failed or have been unable to tolerate previous attempts at systematic therapy or surgery will be specifically recruited.\n\nExclusion Criteria:\n\n1. The presence of a dermatologic or neurologic condition which is determined by the investigator to be the primary cause of the patient's pain.\n2. Allergy to any of the medications or the base itself.\n3. Concurrent use of the following medications. . The patient may enroll in the study after a two week washout from these medications. Patients may need to receive approval from the prescribing physician before stopping these medications. Failure to obtain approval for medication cessation would be cause for exclusion.\n\nGabapentin (NeurontinTM) Amitriptyline (ElavilTM) Nortriptyline (PamelorTM) Desipramine (NorpraminTM) Tramadol (UltramTM, ConZipTM, RybixTM, RysoltTM, Ultram ERTM) Pregabalin (LyricaTM) Baclofen","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Adrienne D Bonham, MD","affiliation":"University of Rochester","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"University of Rochester","city":"Rochester","state":"New York","zip":"14642","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"All Study Participants","description":"Each study subject was sequentially exposed to each of the study drugs and the placebo in a random order. The study is designed as a double blinded, crossover study.\n\nAmitriptyline 2%/ Baclofen 2%: Topical application of the drug at a 2% concentration in combination with 2% Baclofen\n\nKetoprofen: To be applied topically at a 10% concentration\n\nKetamine: To be applied topically at a 10% concentration\n\nLoperamide: To be applied topically at a 5% concentration\n\nGabapentin: To be applied topically at a 6% concentration"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"9"}]},{"type":"Received Placebo","achievements":[{"groupId":"FG000","numSubjects":"9"}]},{"type":"Received Amitriptyline/ Baclofen","achievements":[{"groupId":"FG000","numSubjects":"7"}]},{"type":"Received Ketoprofen","achievements":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"Received Loperamide","achievements":[{"groupId":"FG000","numSubjects":"7"}]},{"type":"Received Ketamine","achievements":[{"groupId":"FG000","numSubjects":"6"}]},{"type":"Received Gabapentin","achievements":[{"groupId":"FG000","numSubjects":"8"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"All Study Participants","description":"Each study subject will be sequentially exposed to each of the study drugs and the placebo in a random order. The study is designed as a double blinded, crossover study.\n\nAmitriptyline/ Baclofen: Topical application of the drug at a 2% concentration in combination with 2% Baclofen\n\nKetoprofen: To be applied topically at a 10% concentration\n\nKetamine: To be applied topically at a 10% concentration\n\nLoperamide: To be applied topically at a 5% concentration\n\nGabapentin: To be applied topically at a 6% concentration"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"9"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"9"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Reduction in Daily Genital Pain.","description":"Each subject was asked to keep a symptom diary recording her daily genital pain, measured on a 10 point Likert scale. A score of \"0\" was defined as no pain and a score of \"10\" was defined as worst imaginable pain. These daily values were collected and a mean pain score for the period of treatment was calculated.","populationDescription":"For each placebo entry the data is limited to include only those participates who also received the named intervention.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"13 weeks","groups":[{"id":"OG000","title":"Medications","description":"Each study subject will be sequentially exposed to each of the study drugs and the placebo in a random order. The study is designed as a double blinded, crossover study.\n\nAmitriptyline: Topical application of the drug at a 2% concentration in combination with 2% Baclofen\n\nBaclofen: Used topically at 2% concentration in combination with 2% amitriptyline\n\nKetoprofen: To be applied topically at a 10% concentration\n\nKetamine: To be applied topically at a 10% concentration\n\nLoperamide: To be applied topically at a 5% concentration\n\nGabapentin: To be applied topically at a 6% concentration"},{"id":"OG001","title":"Placebo","description":"The compounding base alone will be used as a placebo. Each participant will be given each drug and the placebo sequentially in random order.\n\nplacebo: Compounding base to be used alone as a placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Loperamide","categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.94"},{"groupId":"OG001","value":"2.92","spread":"2.3"}]}]},{"title":"Ketamine","categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":"2.45"},{"groupId":"OG001","value":"2.77","spread":"2.46"}]}]},{"title":"Gabapentin","categories":[{"measurements":[{"groupId":"OG000","value":"3.70","spread":"2.92"},{"groupId":"OG001","value":"3.41","spread":"2.55"}]}]},{"title":"amtriptyline/baclofen","categories":[{"measurements":[{"groupId":"OG000","value":"3.87","spread":"2.74"},{"groupId":"OG001","value":"3.61","spread":"2.68"}]}]},{"title":"ketoprofen","categories":[{"measurements":[{"groupId":"OG000","value":"5.05","spread":"3.34"},{"groupId":"OG001","value":"5.05","spread":"3.45"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Null hypothesis - that the improvement in daily genital pain would be no different with the daily application of loperamide than with the daily application of a placebo cream.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.30","statisticalMethod":"t-test, 2 sided","statisticalComment":"Paired T test"},{"groupIds":["OG000","OG001"],"groupDescription":"Null hypothesis - that the improvement in daily genital pain would be no different with the daily application of ketamine than with the daily application of a placebo cream.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.33","statisticalMethod":"t-test, 2 sided","statisticalComment":"Paired"},{"groupIds":["OG000","OG001"],"groupDescription":"Null hypothesis - that the improvement in daily genital pain would be no different with the daily application of gabapentin than with the daily application of a placebo cream.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.65","statisticalMethod":"t-test, 2 sided","statisticalComment":"paired"},{"groupIds":["OG000","OG001"],"groupDescription":"Null hypothesis - that the improvement in daily genital pain would be no different with the daily application of amitriptyline and baclofen than with the daily application of a placebo cream.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.25","statisticalMethod":"t-test, 2 sided","statisticalComment":"Paired"},{"groupIds":["OG000","OG001"],"groupDescription":"Null hypothesis - that the improvement in daily genital pain would be no different with the daily application of ketoprofen than with the daily application of a placebo cream.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1.0","statisticalMethod":"t-test, 2 sided","statisticalComment":"Paired"}]},{"type":"SECONDARY","title":"Reduction in Tampon Test Pain","description":"Reduction in the pain, as measured on a 10 point Likert scale, associated with the insertion and removal of a tampon. This is a validated surrogate for pain associated with intercourse. Subjects were asked to insert and remove a tampon each week and report the degree of pain associated with this. A score of \"0\" was defined as no pain, and a score of \"10\" was defined as worst imaginable pain.","populationDescription":"For each placebo entry the data is limited to include only those participates who also received the named intervention.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"13 weeks","groups":[{"id":"OG000","title":"Medications","description":"Each study subject will be sequentially exposed to each of the study drugs and the placebo in a random order. The study is designed as a double blinded, crossover study.\n\nAmitriptyline: Topical application of the drug at a 2% concentration in combination with 2% Baclofen\n\nBaclofen: Used topically at 2% concentration in combination with 2% amitriptyline\n\nKetoprofen: To be applied topically at a 10% concentration\n\nKetamine: To be applied topically at a 10% concentration\n\nLoperamide: To be applied topically at a 5% concentration\n\nGabapentin: To be applied topically at a 6% concentration"},{"id":"OG001","title":"Placebo","description":"The compounding base alone will be used as a placebo. Each participant will be given each drug and the placebo sequentially in random order.\n\nplacebo: Compounding base to be used alone as a placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"loperamide","categories":[{"measurements":[{"groupId":"OG000","value":"4.71","spread":"2.75"},{"groupId":"OG001","value":"5.29","spread":"3.21"}]}]},{"title":"ketamine","categories":[{"measurements":[{"groupId":"OG000","value":"5.92","spread":"3.56"},{"groupId":"OG001","value":"5.92","spread":"3.00"}]}]},{"title":"gabapentin","categories":[{"measurements":[{"groupId":"OG000","value":"5.125","spread":"3.57"},{"groupId":"OG001","value":"4.875","spread":"3.19"}]}]},{"title":"ketoprofen","categories":[{"measurements":[{"groupId":"OG000","value":"6.17","spread":"3.18"},{"groupId":"OG001","value":"6.0","spread":"3.46"}]}]},{"title":"amitriptyline/baclofen","categories":[{"measurements":[{"groupId":"OG000","value":"5.43","spread":"2.75"},{"groupId":"OG001","value":"5.36","spread":"3.12"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Null hypothesis - that the improvement in tampon test pain would be no different with the daily application of loperamide cream than with the daily application of a placebo cream.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.31","statisticalMethod":"t-test, 2 sided","statisticalComment":"paired"},{"groupIds":["OG000","OG001"],"groupDescription":"Null hypothesis - that the improvement in tampon test pain would be no different with the daily application of ketamine cream than with the daily application of a placebo cream.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1","statisticalMethod":"t-test, 2 sided","statisticalComment":"Paired"},{"groupIds":["OG000","OG001"],"groupDescription":"Null hypothesis - that the improvement in tampon test pain would be no different with the daily application of gabapentin cream than with the daily application of a placebo cream.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.66","statisticalMethod":"t-test, 2 sided","statisticalComment":"Paired"},{"groupIds":["OG000","OG001"],"groupDescription":"Null hypothesis - that the improvement in tampon test pain would be no different with the daily application of ketoprofen cream than with the daily application of a placebo cream.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.42","statisticalMethod":"t-test, 2 sided","statisticalComment":"Paired"},{"groupIds":["OG000","OG001"],"groupDescription":"Null hypothesis - that the improvement in tampon test pain would be no different with the daily application of amitriptyline/baclofen cream than with the daily application of a placebo cream.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.79","statisticalMethod":"t-test, 2 sided","statisticalComment":"Paired"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"1.5 years","eventGroups":[{"id":"EG000","title":"Medications","description":"Each study subject will be sequentially exposed to each of the study drugs and the placebo in a random order. The study is designed as a double blinded, crossover study.\n\nAmitriptyline: Topical application of the drug at a 2% concentration in combination with 2% Baclofen\n\nBaclofen: Used topically at 2% concentration in combination with 2% amitriptyline\n\nKetoprofen: To be applied topically at a 10% concentration\n\nKetamine: To be applied topically at a 10% concentration\n\nLoperamide: To be applied topically at a 5% concentration\n\nGabapentin: To be applied topically at a 6% concentration","seriousNumAffected":0,"seriousNumAtRisk":9,"otherNumAffected":0,"otherNumAtRisk":9},{"id":"EG001","title":"Placebo","description":"The compounding base alone will be used as a placebo. Each participant will be given each drug and the placebo sequentially in random order.\n\nplacebo: Compounding base to be used alone as a placebo","seriousNumAffected":0,"seriousNumAtRisk":9,"otherNumAffected":0,"otherNumAtRisk":9}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"The small number of patients recruited left this study underpowered to uncover significant effects with the medications studied."},"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Adrienne Bonham MD","organization":"University of Rochester","email":"adrienne_bonham@urmc.rochester.edu","phone":"(585) 273-3314"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D005831","term":"Genital Diseases, Female"}],"ancestors":[{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D000091662","term":"Genital Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000639","term":"Amitriptyline"},{"id":"D001418","term":"Baclofen"},{"id":"D007660","term":"Ketoprofen"},{"id":"D007649","term":"Ketamine"},{"id":"D008139","term":"Loperamide"},{"id":"C015715","term":"bismuth subsalicylate"},{"id":"D000077206","term":"Gabapentin"},{"id":"C011189","term":"cetyl alcohol, propylene glycol, sodium lauryl sulfate non-lipid cleansing lotion"}],"ancestors":[{"id":"D003986","term":"Dibenzocycloheptenes"},{"id":"D001567","term":"Benzocycloheptenes"},{"id":"D011084","term":"Polycyclic Aromatic Hydrocarbons"},{"id":"D006841","term":"Hydrocarbons, Aromatic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D011083","term":"Polycyclic Compounds"},{"id":"D005680","term":"gamma-Aminobutyric Acid"},{"id":"D000613","term":"Aminobutyrates"},{"id":"D002087","term":"Butyrates"},{"id":"D000144","term":"Acids, Acyclic"},{"id":"D002264","term":"Carboxylic Acids"},{"id":"D010666","term":"Phenylpropionates"},{"id":"D000146","term":"Acids, Carbocyclic"},{"id":"D003510","term":"Cyclohexanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D010880","term":"Piperidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D000588","term":"Amines"},{"id":"D003509","term":"Cyclohexanecarboxylic Acids"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"}]}},"hasResults":true}